全球乾癬性關節炎治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計乾癬性關節炎治療市場規模將從 2025 年的 210.6 億美元成長到 2034 年的 436.3 億美元，2026 年至 2034 年的複合年成長率為 8.43%。

受自體免疫疾病盛行率上升以及人們對早期診斷和治療意識提升的推動，全球乾癬性關節炎治療市場正穩步成長。乾癬性關節炎常與乾癬相關，需要長期使用生物製藥、緩解疾病抗風濕藥（DMARDs）和標靶治療。患者群體的擴大和診斷能力的提高是推動市場成長的重要因素。

關鍵成長要素包括生物製藥和標靶分子療法的進步，這些療法具有更優的療效和安全性。醫療保健支出的增加、報銷機制的完善以及患者支持計劃的實施，正在加速這些療法的普及。透過臨床試驗和研究舉措持續關注新型免疫調節療法，進一步加劇了競爭格局。

未來，個人化醫療方法和生物相似藥的引入有望提高治療的成本效益和可近性。整合用於疾病監測和病人參與的數位化健康工具也將有助於治療的連續性。免疫療法的持續創新有望維持乾癬性關節炎治療市場的強勁成長。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球乾癬性關節炎治療市場：依藥物類別分類

• 市場分析、洞察與預測
• TNF抑制劑
• 白細胞介素抑制劑
• PDE4抑制劑
• 其他

第5章 全球乾癬性關節炎治療市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外
• 外用

第6章 全球乾癬性關節炎治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第7章 全球乾癬性關節炎治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • AbbVie Inc
  • Janssen Pharmaceutical NV
  • Novartis AG
  • Amgen Inc
  • Celgene Corporation
  • Eli Lilly And Company
  • Bristol Myers Squibb
  • UCB SA
  • Pfizer Inc
  • Sanofi

The Psoriatic Arthritis Therapeutics Market size is expected to reach USD 43.63 Billion in 2034 from USD 21.06 Billion (2025) growing at a CAGR of 8.43% during 2026-2034.

The Global Psoriatic Arthritis Therapeutics Market is growing steadily due to the increasing prevalence of autoimmune disorders and rising awareness about early diagnosis and treatment. Psoriatic arthritis, often associated with psoriasis, requires long-term management using biologics, disease-modifying antirheumatic drugs (DMARDs), and targeted therapies. Expanding patient pools and improved diagnostic capabilities are contributing significantly to market growth.

Key drivers include advancements in biologic drugs and targeted small molecules that offer better efficacy and safety profiles. Increased healthcare spending, improved reimbursement frameworks, and patient support programs are encouraging treatment adoption. Ongoing clinical trials and research initiatives focused on novel immunomodulatory therapies are further strengthening the competitive landscape.

In the future, the market is expected to witness the introduction of personalized medicine approaches and biosimilar products, improving affordability and accessibility. The growing integration of digital health tools for disease monitoring and patient engagement will also support treatment adherence. Continuous innovation in immunotherapy is likely to sustain strong growth in the psoriatic arthritis therapeutics market.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Class

• TNF Inhibitors
• Interleukin Inhibitors
• PDE4 Inhibitors
• Others

By Route of Administration

• Oral
• Parenteral
• Topical

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• AbbVie Inc, Janssen Pharmaceutical NV, Novartis AG, Amgen Inc, Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, UCB SA, Pfizer Inc, Sanofi
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. TNF Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Interleukin Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. PDE4 Inhibitors Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Drug Class
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Drug Class
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Drug Class
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Drug Class
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Drug Class
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL PSORIATIC ARTHRITIS THERAPEUTICS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 AbbVie Inc
  • 9.2.2 Janssen Pharmaceutical NV
  • 9.2.3 Novartis AG
  • 9.2.4 Amgen Inc
  • 9.2.5 Celgene Corporation
  • 9.2.6 Eli Lilly And Company
  • 9.2.7 Bristol Myers Squibb
  • 9.2.8 UCB S.A
  • 9.2.9 Pfizer Inc
  • 9.2.10 Sanofi